Arrowhead Research Corp. (NASDAQ:ARWR) shares saw strong trading volume on Thursday . 2,357,179 shares were traded during mid-day trading, an increase of 270% from the previous session’s volume of 636,817 shares.The stock last traded at $7.15 and had previously closed at $6.34.

A number of brokerages have recently commented on ARWR. William Blair began coverage on Arrowhead Research Corp. in a report on Friday. They set an “outperform” rating for the company. Cantor Fitzgerald began coverage on Arrowhead Research Corp. in a report on Wednesday. They set a “buy” rating and a $15.00 price target for the company. Piper Jaffray Cos. cut their price target on Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Chardan Capital began coverage on Arrowhead Research Corp. in a report on Thursday, May 19th. They set a “buy” rating and a $12.00 price target for the company. Finally, Jefferies Group reiterated a “hold” rating and set a $4.75 price target on shares of Arrowhead Research Corp. in a report on Wednesday, May 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $10.44.

The company’s 50-day moving average price is $5.90 and its 200 day moving average price is $5.28. The stock’s market capitalization is $455.63 million.

Arrowhead Research Corp. (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.05. During the same quarter in the previous year, the business posted ($0.27) earnings per share. The firm had revenue of $39.58 million for the quarter, compared to the consensus estimate of $0.05 million. The firm’s quarterly revenue was down 68.0% compared to the same quarter last year. Equities research analysts predict that Arrowhead Research Corp. will post ($1.31) EPS for the current fiscal year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.